Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.

Northfelt, Donald W.; Dezube, Bruce J.; Thommes, James; Levine, Richard G.; Roenn, Jamie H. Von; Dosik, Gary M.; Rios, Adan; Krown, Susan E.; Dumond, C.; Mamelok, Richard D.

doi:10.1200/jco.1997.15.2.653

Cited by 152 publications

(74 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13 PLD has activity in soft tissue sarcomas in general, 26 -28 and is highly active in KS. [17][18][19]25,33 Both KS and angiosarcoma are tumors of endothelial cells and may, therefore, share some biologic properties. We treated six patients with angiosarcomas with PLD, either as first-line therapy or in patients who experienced PD while receiving paclitaxel.…”

Section: Discussionmentioning

confidence: 99%

“…14 -16 Pegylated-liposomal doxorubicin (PLD) is highly effective and has only minor toxicity in patients with KS, a tumor composed primarily of abnormal endothelial cells. [17][18][19] PLD is a formulation in which doxorubicin is contained in liposomes that are coated with methoxypoly-(ethylene glycol). The methoxypoly-(ethylene glycol) confers a decreased uptake by the reticuloendothelial system, a long half-life in blood (approximately 50 -60 hours), and a different toxicity from nonpegylated liposomes.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

Skubitz

Haddad

2005

Cancer

187

105

View full text Add to dashboard Cite

BACKGROUNDPaclitaxel has unique activity in angiosarcomas of the face and scalp, but its activity in angiosarcomas originating at other sites is less well defined. Paclitaxel and pegylated‐liposomal doxorubicin (PLD) are highly effective in Kaposi sarcoma (KS). Because of the efficacy of PLD in soft tissue sarcoma in general, and in KS in particular, coupled with potential similarities in KS and angiosarcoma, and the apparent activity of paclitaxel in angiosarcomas, the authors treated patients with angiosarcoma with either paclitaxel or PLD as initial chemotherapy.METHODSTo better define the efficacy of these agents in angiosarcoma, the authors reviewed their experience with paclitaxel and PLD in patients with angiosarcoma treated between 1994 and 2004.RESULTSThey identified seven patients with angiosarcoma treated with paclitaxel, and six treated with PLD. Only one patient in the series had an angiosarcoma of the scalp. Two patients receiving paclitaxel had received previous therapy with PLD, and four of six patients treated with PLD had previously received paclitaxel. Of the eight patients treated with paclitaxel, five had major responses (three had partial responses [PR] and two had complete disease remission [CR]) and three had progressive disease (PD). Of the 6 patients who received PLD, 3 had a PR for 6, 19, and >20 months, respectively, 2 had stable disease for 7 and 11 months, respectively, and 1 had PD.CONCLUSIONSThe current study demonstrated the activity of PLD (five of six patients experienced clinical benefit) and extended the data on paclitaxel in angiosarcoma, both of the face and scalp, as well as angiosarcoma originating at other sites. Cancer 2005. © 2005 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

Skubitz

Haddad

2005

Cancer

187

105

View full text Add to dashboard Cite

show abstract

“…Recent successes in this area of clinical research include the efficacy of liposomal doxorubicin in AIDS-related Kaposi's sarcoma and patients with refractory ovarian cancer (Muggia et al, 1997;Northfelt et al, 1997). Although the precise mechanisms by which liposomes selectively enter tumours and release drug are not completely understood, their successful application with doxorubicin has led to a resurgence of interest in this area.…”

Section: Discussionmentioning

confidence: 99%

A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin

et al. 2001

View full text Add to dashboard Cite

Summary Pre-clinical studies indicate that cisplatin encapsulated in STEALTH ® liposomes (SPI-77) retains anti-tumour activity, but has a much reduced toxicity, compared to native cisplatin. A phase I study was conducted to determine the toxicity and pharmacokinetics of SPI-77 administered to children with advanced cancer not amenable to other treatment. Paediatric patients were treated at doses ranging from 40 to 320 mg m -2 by intravenous infusion every 4 weeks. Blood samples taken during, and up to 3 weeks after, administration and plasma and ultrafiltrate were prepared immediately. Urine was collected, when possible, for 3 days after administration. SPI-77 administration was well tolerated with the major toxicity being an infusion reaction which responded to modification of the initial infusion rate of SPI-77. Limited haematological toxicity and no nephrotoxicity were observed. No responses to treatment were seen during the course of this phase I study. Measurement of total plasma platinum showed that cisplatin was retained in the circulation with a half life of up to 134 h, with maximum plasma concentrations approximately 100-fold higher than those reported following comparable doses of cisplatin. Comparison of plasma and whole blood indicated that cisplatin was retained in the liposomes and there was no free platinum measurable in the ultrafiltrate. Urine recovery was less than 4% of the dose administered over 72 h. Results from this phase I study indicate that high doses of liposomal cisplatin can safely be given to patients, but further studies are required to address the issue of reformulation of liposomally bound cisplatin.

show abstract

“…ABV patients experienced significantly more alopecia and neuropathy, while liposomal daunorubicin patients had significantly more grade 4 neutropenia. A second study gave liposomal doxorubicin to 53 patients with AIDSrelated KS who had progressed through or were intolerant to combination therapy [90]. The study demonstrated a 36% PR rate and a median duration of response Ͼ4 months, helping to establish liposomal doxorubicin as a reasonable second-line drug.…”

Section: Treatmentmentioning

confidence: 99%

Malignancy After Solid Organ Transplantation: An Overview

2008

View full text Add to dashboard Cite

Disclosure:This article discusses the use of acitretin (manufactured by Connetics) for prophylaxis of non-melanoma skin cancers; cyclophosphamide * (Bristol-Myers Squibb), adriamycin * (Pharmacia), prednisone * (Pfizer), vindesine (Lilly/EG Labo; not available in the U.S.), rituximab * (Genentech), and monoclonal anti-IL-6-antibody (multiple manufacturers) for post-transplant lymphoproliferative disorder (PTLD) (clinical trial); vincristine * (Lilly/Gensia Sicor) and bleomycin * (Bristol-Myers Squibb) for PTLD and Kaposi's sarcoma (KS); liposomal daunorubicin (Gilead) for KS (indicated for HIV-associated KS); paclitaxel (BristolMyers Squibb) for KS (indicated for AIDS-associated KS); imatinib (Novartis) and bevacizumab (Genentech) for KS; and matrix metalloproteinase inhibitor COL-3 (CollaGenex) for KS (clinical trial). ( * Drugs marked with asterisks are indicated for use in malignant lymphomas generally, but no specific mention is made of PTLD.)The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers. LEARNING OBJECTIVESAfter completing this course, the reader should be able to:1. Describe the most common malignancies encountered after solid organ transplantation.2. Discuss the pathogenesis of malignancy after solid organ transplantation. Administer standard treatment for common post-solid organ transplantation malignancies.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACT CASE PRESENTATIONA 49-year-old man with no prior medical history initially presented with severe dyspnea progressive over 6 months.The patient underwent an open-lung biopsy that confirmed the diagnosis of idiopathic pulmonary fibrosis. He was assessed for lung transplantation. An extensive pretransplant

show abstract

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.

Abstract: Pegylated-liposomal doxorubicin offers a new alternative for treatment of patients who have experienced failure of standard chemotherapy for AIDS-KS.

Cited by 152 publications

References 10 publications

Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin

Malignancy After Solid Organ Transplantation: An Overview

Contact Info

Product

Resources

About